NCT05419479 2026-02-24
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
Phase 1/2 Suspended
Clinical Trials
9 trialsNCT06048133 2026-01-23
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT07283848 2025-12-26
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT05024097 2025-08-27
PANTHER
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05724563 2025-05-21
Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT06166589 2023-12-12
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06009029 2023-08-24
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT05540483 2022-09-16
RIGHT
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown